The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic; Preventive drugs may be the best solution to the antibiotic resistance crisis

Taking stock of the drug industry, from the lab to the medicine chest

October 18, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Christine Kao/STAT STAT+ | The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic Analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs. By Damian Garde STAT+ | Opinion: Preventive drugs may be the best solution to the antibiotic resistance crisis Lumen Bioscience CEO Brian Finrow writes, "There's an underappreciated solution to the broken market for antimicrobials." By Brian Finrow STAT+ | Why doesn't everyone lose weight on Ozempic-type drugs? Researchers look for genetic clues Because of the wide range of response to GLP-1s, a search is on for data that would help steer patients to effective obesity treatments. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser